FDA warned Ketdaxandrugs it sells unapproved, misbranded ketamine "KETAMINE CRYSTAL" online without prescriptions to U.S. consumers.
What happened
FDA reviewed the website www.ketdaxandrugs.org (FEI 3043544188) on February 26, 2026; this was a website review, not an inspection. FDA found the site offering ketamine marketed as "KETAMINE CRYSTAL" for human use with no FDA-approved application, no adequate directions for use, and without requiring a prescription. FDA noted that approved ketamine is an injectable controlled substance, and that approved esketamine (SPRAVATO) carries a boxed warning and is sold only through a restricted safety program (REMS).
What FDA found
The company sold ketamine as a new drug without an FDA-approved application.
FD&C Act sections 301(d) and 505(a) (21 U.S.C. 331(d), 355(a))The product's labeling does not give adequate directions for use.
FD&C Act section 502(f)(1) (21 U.S.C. 352(f)(1))The product is not exempt from the directions requirement because it is not approved in the United States.
21 CFR 201.115(a)The company offers a prescription drug without requiring a prescription, so the drug is misbranded while held for sale.
FD&C Act sections 503(b)(1) and 301(k) (21 U.S.C. 353(b)(1), 331(k))Website claims show the product is intended for human use as a drug.
21 CFR 201.128
What FDA wants
FDA asks the company to stop offering any unapproved and misbranded drugs for sale to U.S. consumers. It must send a written response within 15 business days of receiving the letter, listing the corrections made, steps to prevent repeat violations, and supporting documents, citing reference number MARCS-CMS 725155.
Who should pay attention
- online sellers and telehealth sites offering ketamine products
- clinics and compounding pharmacies marketing ketamine
- consumers buying prescription drugs from unverified websites
This is a summary. Read the original letter on fda.gov.